Symbols / COLL
COLL Chart
About
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 1.18B |
| Enterprise Value | 1.73B | Income | 62.87M | Sales | 780.57M |
| Book/sh | 9.51 | Cash/sh | 12.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 423 | IPO | — |
| P/E | 21.54 | Forward P/E | 6.11 | PEG | — |
| P/S | 1.52 | P/B | 3.92 | P/C | — |
| EV/EBITDA | 4.13 | EV/Sales | 2.22 | Quick Ratio | 1.36 |
| Current Ratio | 1.57 | Debt/Eq | 310.41 | LT Debt/Eq | — |
| EPS (ttm) | 1.73 | EPS next Y | 6.10 | EPS Growth | 31.50% |
| Revenue Growth | 12.90% | Earnings | 2026-05-07 | ROA | 7.27% |
| ROE | 23.70% | ROIC | — | Gross Margin | 88.47% |
| Oper. Margin | 30.04% | Profit Margin | 8.05% | Shs Outstand | 31.75M |
| Shs Float | 29.61M | Short Float | 18.08% | Short Ratio | 11.69 |
| Short Interest | — | 52W High | 50.79 | 52W Low | 23.23 |
| Beta | 0.68 | Avg Volume | 462.41K | Volume | 489.06K |
| Target Price | $53.83 | Recom | Buy | Prev Close | $37.29 |
| Price | $37.27 | Change | -0.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$53.83
Mean price target
2. Current target
$37.27
Latest analyst target
3. DCF / Fair value
$182.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$37.27
Low
$44.00
High
$60.00
Mean
$53.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | Needham | Buy → Buy | $54 |
| 2026-01-09 | main | Barclays | Overweight → Overweight | $56 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $60 |
| 2026-01-08 | main | Needham | Buy → Buy | $56 |
| 2025-12-09 | init | Barclays | — → Overweight | $58 |
| 2025-11-07 | main | Truist Securities | Buy → Buy | $48 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $46 |
| 2025-10-28 | reit | Needham | Buy → Buy | $46 |
| 2025-05-09 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2025-04-09 | reit | Needham | Buy → Buy | $46 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-02-04 | main | Piper Sandler | Neutral → Neutral | $36 |
| 2025-01-10 | up | Needham | Hold → Buy | $46 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-10-11 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2024-09-05 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-08-09 | reit | Piper Sandler | Neutral → Neutral | $37 |
| 2024-08-09 | main | Truist Securities | Buy → Buy | $42 |
| 2024-08-09 | reit | Needham | — → Hold | — |
| 2024-07-30 | up | HC Wainwright & Co. | Neutral → Buy | $47 |
- Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today - Yahoo Finance Fri, 27 Feb 2026 08
- (COLL) Volatility Zones as Tactical Triggers - Stock Traders Daily Sat, 07 Mar 2026 00
- Will COLL stock reach all time highs in 2026 - July 2025 Spike Watch & Low Volatility Stock Suggestions - Naître et grandir Sat, 07 Mar 2026 13
- Collegium Pharmaceutical plans four Miami investor events in March - Stock Titan Mon, 02 Mar 2026 13
- COLLEGIUM PHARMACEUTICAL ($COLL) Releases Q4 2025 Earnings - Quiver Quantitative hu, 26 Feb 2026 08
- A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance - simplywall.st Sun, 01 Mar 2026 08
- Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 - The Motley Fool Wed, 14 Jan 2026 08
- Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down on Disappointing Earnings - MarketBeat hu, 26 Feb 2026 08
- Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect - Finviz ue, 24 Feb 2026 08
- Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say - Nasdaq hu, 26 Feb 2026 17
- Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? - Yahoo Finance ue, 18 Nov 2025 08
- Is Collegium Pharmaceutical (COLL) Pricing Look Attractive After Strong Multi‑Year Share Gains? - simplywall.st ue, 24 Feb 2026 08
- Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates - Yahoo Finance hu, 26 Feb 2026 08
- Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? - Yahoo Finance Mon, 22 Dec 2025 08
- Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 49976 | 2019437 | — | Sale at price 40.36 - 40.99 per share. | DREYER SCOTT | Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 49725 | — | — | Stock Award(Grant) at price 0.00 per share. | DREYER SCOTT | Officer | — | 2026-02-10 00:00:00 | D |
| 2 | 37042 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH THOMAS BRAIN M.D. | Officer | — | 2026-02-10 00:00:00 | D |
| 3 | 59155 | — | — | Stock Award(Grant) at price 0.00 per share. | TUPPER COLLEEN | Chief Financial Officer | — | 2026-02-10 00:00:00 | D |
| 4 | 31199 | — | — | Stock Award(Grant) at price 0.00 per share. | DIETER DAVID | General Counsel | — | 2026-02-10 00:00:00 | D |
| 5 | 111795 | — | — | Stock Award(Grant) at price 0.00 per share. | KARNANI VIKRAM | Chief Executive Officer | — | 2026-02-10 00:00:00 | D |
| 6 | 17600 | 847855 | — | Sale at price 47.89 - 48.66 per share. | DREYER SCOTT | Officer | — | 2025-12-08 00:00:00 | D |
| 7 | 17600 | 279840 | — | Conversion of Exercise of derivative security at price 15.90 per share. | DREYER SCOTT | Officer | — | 2025-12-08 00:00:00 | D |
| 8 | 3650 | 171673 | — | Sale at price 47.03 per share. | BALICE-GORDON RITA J | Director | — | 2025-12-05 00:00:00 | D |
| 9 | 34853 | 1645536 | — | Sale at price 47.21 per share. | FALLON JOHN A | Director | — | 2025-11-12 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.76M | -2.51M | -8.56M | 0.00 |
| TaxRateForCalcs | 0.32 | 0.30 | 0.36 | 0.13 |
| NormalizedEBITDA | 415.82M | 350.12M | 331.83M | 173.31M |
| TotalUnusualItems | -14.81M | -8.41M | -23.50M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -14.81M | -8.41M | -23.50M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 62.87M | 69.19M | 48.16M | -25.00M |
| ReconciledDepreciation | 226.07M | 169.16M | 149.26M | 138.94M |
| ReconciledCostOfRevenue | 317.31M | 254.10M | 240.60M | 254.44M |
| EBITDA | 401.00M | 341.70M | 308.33M | 173.31M |
| EBIT | 174.93M | 172.54M | 159.07M | 34.37M |
| NetInterestIncome | -71.02M | -60.00M | -67.72M | -62.17M |
| InterestExpense | 82.31M | 73.97M | 83.34M | 63.21M |
| InterestIncome | 11.29M | 13.98M | 15.62M | 1.05M |
| NormalizedIncome | 72.92M | 75.10M | 63.10M | -25.00M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 62.87M | 69.19M | 48.16M | -25.00M |
| TotalExpenses | 602.11M | 464.47M | 399.81M | 430.61M |
| TotalOperatingIncomeAsReported | 179.64M | 169.90M | 166.96M | 33.32M |
| DilutedAverageShares | 39.70M | 40.42M | 41.79M | 33.83M |
| BasicAverageShares | 31.71M | 32.27M | 33.74M | 33.83M |
| DilutedEPS | 1.73 | 1.86 | 1.29 | -0.74 |
| BasicEPS | 1.98 | 2.14 | 1.43 | -0.74 |
| DilutedNIAvailtoComStockholders | 68.88M | 75.05M | 54.04M | -25.00M |
| AverageDilutionEarnings | 6.01M | 5.86M | 5.89M | 0.00 |
| NetIncomeCommonStockholders | 62.87M | 69.19M | 48.16M | -25.00M |
| NetIncome | 62.87M | 69.19M | 48.16M | -25.00M |
| NetIncomeIncludingNoncontrollingInterests | 62.87M | 69.19M | 48.16M | -25.00M |
| NetIncomeContinuousOperations | 62.87M | 69.19M | 48.16M | -25.00M |
| TaxProvision | 29.75M | 29.38M | 27.58M | -3.85M |
| PretaxIncome | 92.62M | 98.57M | 75.73M | -28.85M |
| OtherIncomeExpense | -14.81M | -8.41M | -23.50M | -4.58M |
| SpecialIncomeCharges | -14.81M | -8.41M | -23.50M | 0.00 |
| OtherSpecialCharges | 15.99M | 11.33M | 23.50M | |
| RestructuringAndMergernAcquisition | -1.18M | -2.91M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | -71.02M | -60.00M | -67.72M | -62.17M |
| InterestExpenseNonOperating | 82.31M | 73.97M | 83.34M | 63.21M |
| InterestIncomeNonOperating | 11.29M | 13.98M | 15.62M | 1.05M |
| OperatingIncome | 178.45M | 166.98M | 166.96M | 33.32M |
| OperatingExpense | 284.80M | 210.36M | 159.21M | 176.17M |
| ResearchAndDevelopment | 0.00 | 0.00 | 3.98M | 9.45M |
| SellingGeneralAndAdministration | 284.80M | 210.36M | 159.21M | 172.19M |
| GrossProfit | 463.26M | 377.34M | 326.17M | 209.49M |
| CostOfRevenue | 317.31M | 254.10M | 240.60M | 254.44M |
| TotalRevenue | 780.57M | 631.45M | 566.77M | 463.93M |
| OperatingRevenue | 780.57M | 631.45M | 566.77M | 463.93M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 9.03M | 8.21M | 6.32M | 3.24M |
| OrdinarySharesNumber | 31.71M | 31.44M | 31.87M | 33.85M |
| ShareIssued | 40.74M | 39.65M | 38.19M | 37.08M |
| NetDebt | 578.07M | 781.92M | 428.22M | 527.26M |
| TotalDebt | 814.86M | 859.30M | 674.28M | 709.17M |
| TangibleBookValue | -513.76M | -824.89M | -360.13M | -506.32M |
| InvestedCapital | 1.11B | 1.08B | 862.60M | 895.79M |
| WorkingCapital | 251.38M | -27.25M | 79.69M | -13.74M |
| NetTangibleAssets | -513.76M | -824.89M | -360.13M | -506.32M |
| CapitalLeaseObligations | 5.54M | 6.81M | 7.11M | 8.22M |
| CommonStockEquity | 301.68M | 228.84M | 195.43M | 194.84M |
| TotalCapitalization | 1.08B | 1.02B | 679.27M | 733.29M |
| TotalEquityGrossMinorityInterest | 301.68M | 228.84M | 195.43M | 194.84M |
| StockholdersEquity | 301.68M | 228.84M | 195.43M | 194.84M |
| GainsLossesNotAffectingRetainedEarnings | 319.00K | 55.00K | 14.00K | 0.00 |
| OtherEquityAdjustments | 319.00K | 55.00K | 14.00K | |
| TreasuryStock | 222.51M | 197.50M | 137.38M | 61.92M |
| RetainedEarnings | -101.13M | -164.00M | -233.19M | -281.34M |
| AdditionalPaidInCapital | 624.95M | 590.25M | 565.95M | 538.07M |
| CapitalStock | 41.00K | 40.00K | 38.00K | 37.00K |
| CommonStock | 41.00K | 40.00K | 38.00K | 37.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.36B | 1.43B | 947.88M | 979.29M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 915.13M | 925.24M | 489.96M | 545.56M |
| OtherNonCurrentLiabilities | 1.18M | |||
| NonCurrentDeferredLiabilities | 130.67M | 130.61M | 0.00 | |
| NonCurrentDeferredRevenue | 9.11M | 10.00M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 784.46M | 793.44M | 489.96M | 545.56M |
| LongTermCapitalLeaseObligation | 4.13M | 5.54M | 6.12M | 7.11M |
| LongTermDebt | 780.33M | 787.90M | 483.84M | 538.45M |
| CurrentLiabilities | 440.03M | 509.51M | 457.92M | 433.73M |
| OtherCurrentLiabilities | 2.44M | 3.04M | ||
| CurrentDeferredLiabilities | 667.00K | 0.00 | ||
| CurrentDeferredRevenue | 667.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 30.41M | 65.85M | 184.32M | 163.61M |
| CurrentCapitalLeaseObligation | 1.41M | 1.27M | 988.00K | 1.11M |
| CurrentDebt | 29.00M | 64.58M | 183.33M | 162.50M |
| OtherCurrentBorrowings | 29.00M | 64.58M | 183.33M | 162.50M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.71M | 4.56M | 1.38M | 1.51M |
| PayablesAndAccruedExpenses | 402.81M | 436.05M | 272.22M | 268.61M |
| CurrentAccruedExpenses | 363.55M | 387.97M | 256.38M | 260.76M |
| InterestPayable | 12.02M | 6.15M | 2.85M | 1.41M |
| Payables | 39.25M | 48.08M | 15.84M | 7.85M |
| OtherPayable | 17.57M | 28.96M | ||
| TotalTaxPayable | 11.03M | 15.19M | 7.15M | 4.35M |
| IncomeTaxPayable | 3.30M | 8.53M | 2.14M | 0.00 |
| AccountsPayable | 10.66M | 3.93M | 8.69M | 3.49M |
| TotalAssets | 1.66B | 1.66B | 1.14B | 1.17B |
| TotalNonCurrentAssets | 965.42M | 1.18B | 605.71M | 754.14M |
| OtherNonCurrentAssets | 21.25M | 9.41M | 1.87M | 2.65M |
| NonCurrentDeferredAssets | 112.54M | 98.03M | 26.26M | 23.95M |
| NonCurrentDeferredTaxesAssets | 112.54M | 98.03M | 26.26M | 23.95M |
| GoodwillAndOtherIntangibleAssets | 815.43M | 1.05B | 555.57M | 701.16M |
| OtherIntangibleAssets | 669.51M | 891.40M | 421.71M | 567.47M |
| Goodwill | 145.93M | 162.33M | 133.86M | 133.69M |
| NetPPE | 16.20M | 20.15M | 22.01M | 26.38M |
| AccumulatedDepreciation | -16.54M | -13.53M | -9.68M | -6.32M |
| GrossPPE | 32.74M | 33.69M | 31.69M | 32.70M |
| Leases | 1.23M | 1.23M | 1.06M | 874.00K |
| ConstructionInProgress | 1.75M | 802.00K | 0.00 | 0.00 |
| OtherProperties | 25.77M | 27.06M | 27.11M | 28.21M |
| MachineryFurnitureEquipment | 3.99M | 4.59M | 3.52M | 3.62M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 691.41M | 482.26M | 537.60M | 419.99M |
| OtherCurrentAssets | 3.24M | 2.74M | 93.00K | 57.00K |
| RestrictedCash | 19.85M | 25.00M | 0.00 | |
| PrepaidAssets | 29.40M | 27.65M | 15.10M | 16.62M |
| Inventory | 40.91M | 35.56M | 32.33M | 46.50M |
| FinishedGoods | 15.21M | 16.23M | 12.70M | |
| WorkInProcess | 6.74M | 24.67M | 1.01M | |
| RawMaterials | 10.38M | 5.60M | 3.69M | |
| Receivables | 211.33M | 228.54M | 179.53M | 183.12M |
| AccountsReceivable | 211.33M | 228.54M | 179.53M | 183.12M |
| CashCashEquivalentsAndShortTermInvestments | 386.68M | 162.76M | 310.55M | 173.69M |
| OtherShortTermInvestments | 155.43M | 92.20M | 71.60M | 0.00 |
| CashAndCashEquivalents | 231.25M | 70.56M | 238.95M | 173.69M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 327.58M | 203.33M | 274.29M | 122.61M |
| RepurchaseOfCapitalStock | -25.10M | -60.02M | -75.00M | -14.06M |
| RepaymentOfDebt | -635.56M | -305.66M | -301.14M | -75.00M |
| IssuanceOfDebt | 565.17M | 313.18M | 235.22M | 517.68M |
| CapitalExpenditure | -1.74M | -1.65M | -461.00K | -1.62M |
| InterestPaidSupplementalData | 68.76M | 62.43M | 73.26M | 52.53M |
| IncomeTaxPaidSupplementalData | 60.04M | 52.09M | 24.20M | 10.40M |
| EndCashPosition | 252.16M | 96.61M | 239.99M | 176.24M |
| BeginningCashPosition | 96.61M | 239.99M | 176.24M | 188.97M |
| ChangesInCash | 155.55M | -143.38M | 63.76M | -12.74M |
| FinancingCashFlow | -110.25M | -60.60M | -140.18M | 436.72M |
| CashFlowFromContinuingFinancingActivities | -110.25M | -60.60M | -140.18M | 436.72M |
| NetOtherFinancingCharges | -20.40M | -19.17M | -8.36M | -4.04M |
| ProceedsFromStockOptionExercised | 5.64M | 11.07M | 9.10M | 12.15M |
| NetCommonStockIssuance | -25.10M | -60.02M | -75.00M | -14.06M |
| CommonStockPayments | -25.10M | -60.02M | -75.00M | -14.06M |
| NetIssuancePaymentsOfDebt | -70.38M | 7.52M | -65.92M | 442.68M |
| NetLongTermDebtIssuance | -70.38M | 7.52M | -65.92M | 442.68M |
| LongTermDebtPayments | -635.56M | -305.66M | -301.14M | -75.00M |
| LongTermDebtIssuance | 565.17M | 313.18M | 235.22M | 517.68M |
| InvestingCashFlow | -63.53M | -287.76M | -70.81M | -573.69M |
| CashFlowFromContinuingInvestingActivities | -63.53M | -287.76M | -70.81M | -573.69M |
| NetInvestmentPurchaseAndSale | -61.79M | -18.57M | -70.35M | 0.00 |
| SaleOfInvestment | 65.18M | 92.60M | 22.00M | 0.00 |
| PurchaseOfInvestment | -126.97M | -111.17M | -92.35M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -267.54M | 0.00 | -572.07M |
| PurchaseOfBusiness | 0.00 | -267.54M | 0.00 | -572.07M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -1.74M | -1.65M | -461.00K | -1.62M |
| PurchaseOfPPE | -1.74M | -1.65M | -461.00K | -1.62M |
| OperatingCashFlow | 329.32M | 204.98M | 274.75M | 124.23M |
| CashFlowFromContinuingOperatingActivities | 329.32M | 204.98M | 274.75M | 124.23M |
| ChangeInWorkingCapital | 3.76M | -54.98M | 21.73M | -12.71M |
| ChangeInOtherWorkingCapital | -197.00K | 3.00K | ||
| ChangeInOtherCurrentLiabilities | 0.00 | |||
| ChangeInPayablesAndAccruedExpense | 74.00K | -50.42M | 2.53M | -34.60M |
| ChangeInAccruedExpense | -6.64M | -39.14M | -2.53M | -33.90M |
| ChangeInPayable | 6.72M | -11.28M | 5.06M | -707.00K |
| ChangeInAccountPayable | 6.72M | -11.28M | 5.06M | -707.00K |
| ChangeInPrepaidAssets | -7.97M | -14.07M | 1.44M | -4.61M |
| ChangeInInventory | -5.35M | 13.93M | 14.17M | 48.27M |
| ChangeInReceivables | 17.20M | -4.41M | 3.59M | -21.78M |
| ChangesInAccountReceivables | 17.20M | -4.41M | 3.59M | -21.78M |
| OtherNonCashItems | 5.45M | 6.72M | 8.36M | 8.52M |
| StockBasedCompensation | 41.91M | 32.40M | 27.14M | 22.87M |
| AmortizationOfSecurities | -1.07M | -2.03M | -1.24M | 0.00 |
| DeferredTax | -25.66M | -26.81M | -2.15M | -8.39M |
| DeferredIncomeTax | -25.66M | -26.81M | -2.15M | -8.39M |
| DepreciationAmortizationDepletion | 226.07M | 169.16M | 149.26M | 138.94M |
| DepreciationAndAmortization | 226.07M | 169.16M | 149.26M | 138.94M |
| AmortizationCashFlow | 221.89M | 165.30M | 145.76M | 136.25M |
| AmortizationOfIntangibles | 221.89M | 165.30M | 145.76M | 136.25M |
| Depreciation | 4.18M | 3.86M | 3.50M | 2.68M |
| OperatingGainsLosses | 15.99M | 11.33M | 23.50M | |
| NetIncomeFromContinuingOperations | 62.87M | 69.19M | 48.16M | -25.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COLL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|